
Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission
Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.

Presentation highlights from the ADVENT symposium on disease remission in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.

Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.

Join Profs. Shigeharu Fujieda, Peter Hellings, and Eugenio De Corso for an educational symposium on the evolving understanding of disease control and clinical remission in CRSwNP.

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier revisits a patient case study where a biologic has been added to an asthma management plan and describes the potential for this patient to achieve on-therapy clinical remission.
Watch as Leonard Bacharier, MD, and Sharon Dell, MD, FRCPC, discuss the concept of clinical remission in pediatric severe asthma.

In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Sharon Dell highlights the available clinical biologic efficacy data in pediatric severe asthma, suggesting the potential for achieving clinical remission when added to an asthma management plan.